Oslo University Hospital HF
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Department of Cardiology at Oslo University Hospital HF drives forward innovative care for complex heart conditions. Current investigations assess heart transplantation outcomes and strategies to preserve renal function in transplant recipients.
- Heart transplantation outcomes
- Renal protection after cardiac allograft
- Tacrolimus minimization in low‑risk transplant recipients
- Long‑term safety of subcutaneous immune checkpoint inhibitors in cardiac patients
Across the site, 13 clinical trials involve 20 investigators, with several focused on cardiovascular health.
Digestive System Diseases
Research on digestive system diseases aims to improve therapeutic options for both rare and common gastrointestinal disorders. A priority study examines primary sclerosing cholangitis and its impact on liver function.
- Primary sclerosing cholangitis
- Resectable dMMR/MSI‑H colon cancer
- Advanced colorectal cancer therapies
- Liver involvement in mesothelioma
The portfolio includes trials on colon cancer staging and advanced cholangiopathy, contributing to the overall 13 studies conducted at the site.
Hemic and Lymphatic Diseases
The hematology program focuses on blood‑related disorders and immune deficiencies. A major effort evaluates haemophilia A treatment using extended‑half‑life factor concentrates.
- Haemophilia A management
- Acute lymphoblastic leukemia in infants
- Atypical teratoid/rhabdoid tumours (ATRT) in young children
- Kidney failure and transplantation outcomes
These efforts are part of the broader clinical research activity involving 20 investigators at Oslo University Hospital HF.
Neoplasms
Oncologic trials at the centre target a wide range of solid tumours, seeking to extend survival and reduce disease burden. One prominent study investigates KRAS‑mutated non‑small cell lung cancer with a novel targeted agent.
- KRAS G12C‑mutated NSCLC
- Malignant pleural mesothelioma
- Metastatic melanoma immunotherapy
- HPV‑positive oropharyngeal carcinoma
- dMMR/MSI‑H colon cancer
The neoplasm portfolio contributes several of the 13 active trials, reflecting the institution’s commitment to cancer research.
Respiratory Tract Diseases
Respiratory research centers on lung malignancies and mesothelioma, exploring new immunologic and targeted strategies. Current work assesses malignant pleural mesothelioma response to combination therapies.
- Malignant pleural mesothelioma
- KRAS‑mutated NSCLC
- Advanced lung cancer immunotherapy
- Bronchial involvement in HPV‑related cancers
These respiratory studies form a key component of the hospital’s 13‑trial clinical program.
Virus Diseases
The virology unit addresses emerging infectious threats and evaluates therapeutic options. A focused trial measures the efficacy of treatment for monkeypox infections.
- Monkeypox therapeutic trial
- Evaluation of antiviral agents
- Safety monitoring of viral vaccine candidates
- Diagnostic improvement for viral infections
Viral disease investigations complement the broader research agenda at Oslo University Hospital HF.
Other Research Areas
Some studies span multiple specialties or address rare conditions that do not fit conventional categories. An interdisciplinary project examines atypical teratoid/rhabdoid tumours in infants using novel consolidation regimens.
- Atypical teratoid/rhabdoid tumours in children
- Kidney transplantation immunosuppression minimization
- Peri‑operative dostarlimab in early‑stage colon cancer
- Physical activity monitoring in severe haemophilia A
These cross‑disciplinary efforts are included among the 13 trials conducted by 20 investigators at the Oslo University Hospital HF.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 56 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 56 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1St. Olavs Hospital HF2active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Oslo University Hospital HF5trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Oslo University Hospital HF
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicentre, triple blind, placebo controlled, parallel group study of atorvastatin in chronic migraine | St. Olavs Hospital HF | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 56 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Nivolumab | 3 | Unknown | 2019-12-20 | 2024-04-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.